...
首页> 外文期刊>Pediatric dermatology >Ulcerated Infantile Hemangioma: Novel Treatment with Topical Brimonidine-Timolol
【24h】

Ulcerated Infantile Hemangioma: Novel Treatment with Topical Brimonidine-Timolol

机译:溃疡性小儿血管瘤:局部使用溴莫尼定-替莫洛尔的新型治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We report a 2-month-old boy with a painful ulcerated hemangioma on the lower mucosal lip extending to the vermillion border that caused feeding difficulty. It was successfully treated with topical brimonidine 0.2% and timolol 0.5%, a combination selective alpha(2)-adrenergic agonist and nonselective beta-blocker. After 6 weeks of treatment, the lesion reepithelialized and the patient's symptoms and functional complications resolved. Brimonidine 0.2% timolol 0.5% ophthalmic solution is an emerging alternative treatment for hemangiomas, offering the potential to target hemangioma growth through two synergistic mechanisms (beta-inhibition and alpha(2)-agonism) that may be especially effective for ulcerated lesions, the most common complication of infantile hemangiomas.
机译:我们报道了一个2个月大的男孩,其下黏膜唇部有溃疡性血管瘤疼痛,延伸至朱红色边界,导致进食困难。它已成功地用0.2%的溴莫尼定和0.5%的替莫洛尔,选择性α(2)-肾上腺素能激动剂和非选择性β-受体阻滞剂联合治疗。治疗6周后,病变再次上皮化,患者的症状和功能并发症得以解决。溴莫尼定0.2%噻吗洛尔0.5%眼药水是一种新兴的血管瘤替代治疗方法,它有可能通过两种协同机制(β抑制和α(2)-激动作用)靶向血管瘤生长,这对溃疡性病变尤其有效婴儿血管瘤的常见并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号